D-1498-2022 Class II Terminated

Recalled by CIPLA — Warren, NJ

FDA drug recall D-1498-2022 was initiated by CIPLA on Aug 22, 2022 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility. The recall status is terminated (terminated Nov 27, 2023). Affected quantity: 3,468 bottles.

Recall Details

Product Type
Drugs
Report Date
Sep 14, 2022
Initiation Date
Aug 22, 2022
Termination Date
Nov 27, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,468 bottles

Product Description

Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured for Exelan Pharmecuticals, Inc., Boca Raton, FL 33432, NDC 76282-708-50.

Reason for Recall

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

Distribution Pattern

Nationwide in the USA

Code Information

Lot # DEG5BD2, Exp 07/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1498-2022
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1498-2022. Report a data issue: hello@regdatalab.com.